DE69630691D1 - LIPOSOMEN MIT p-ETHOXYOLIGONUKLEOTIDEN - Google Patents

LIPOSOMEN MIT p-ETHOXYOLIGONUKLEOTIDEN

Info

Publication number
DE69630691D1
DE69630691D1 DE69630691T DE69630691T DE69630691D1 DE 69630691 D1 DE69630691 D1 DE 69630691D1 DE 69630691 T DE69630691 T DE 69630691T DE 69630691 T DE69630691 T DE 69630691T DE 69630691 D1 DE69630691 D1 DE 69630691D1
Authority
DE
Germany
Prior art keywords
oligonucleotides
liposome
ethoxyoligonucleotids
liposomes
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69630691T
Other languages
English (en)
Other versions
DE69630691T2 (de
Inventor
Gabriel Lopez-Berestein
Maria Tari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of DE69630691D1 publication Critical patent/DE69630691D1/de
Application granted granted Critical
Publication of DE69630691T2 publication Critical patent/DE69630691T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Silicon Polymers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69630691T 1995-08-29 1996-08-26 Liposomal p-Ethoxy Oligonucleotides Expired - Lifetime DE69630691T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US520385 1995-08-29
US08/520,385 US5855911A (en) 1995-08-29 1995-08-29 Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
PCT/US1996/014146 WO1997007784A2 (en) 1995-08-29 1996-08-26 LIPOSOMAL PHOSPHODIESTER, PHOSPHOROTHIOATE, AND p-ETHOXY OLIGONUCLEOTIDES

Publications (2)

Publication Number Publication Date
DE69630691D1 true DE69630691D1 (de) 2003-12-18
DE69630691T2 DE69630691T2 (de) 2004-11-25

Family

ID=24072378

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69630691T Expired - Lifetime DE69630691T2 (de) 1995-08-29 1996-08-26 Liposomal p-Ethoxy Oligonucleotides

Country Status (11)

Country Link
US (4) US5855911A (de)
EP (1) EP0847272B1 (de)
JP (1) JP4291412B2 (de)
AT (1) ATE253897T1 (de)
AU (1) AU6912996A (de)
CA (1) CA2228944C (de)
DE (1) DE69630691T2 (de)
DK (1) DK0847272T3 (de)
ES (1) ES2210385T3 (de)
PT (1) PT847272E (de)
WO (1) WO1997007784A2 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6894031B1 (en) * 1996-11-21 2005-05-17 Cedars-Sinai Medical Center Pituitary tumor transforming gene (PTTG) carboxy-terminal peptides and methods of use thereof to inhibit neoplastic cellular proliferation and/or transformation
US6565889B2 (en) * 1996-12-02 2003-05-20 The Regents Of The University Of California Bilayer structure which encapsulates multiple containment units and uses thereof
US7262173B2 (en) 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
WO1998051278A2 (en) * 1997-05-14 1998-11-19 Inex Pharmaceuticals Corporation High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
CA2294579C (en) * 1997-06-23 2007-10-09 Sequus Pharmaceuticals, Inc. Liposome-entrapped polynucleotide composition and method
WO1999001579A1 (en) * 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
DE19740092A1 (de) * 1997-09-12 1999-03-18 Ulrich Dr Med Hengge Liposomen und Verfahren zur Transfektion von Zellen
US7285288B1 (en) * 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) * 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
ATE385237T1 (de) 1999-02-26 2008-02-15 Univ British Columbia Antisense-therapie für trpm-2
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
AU7868400A (en) 1999-10-08 2001-04-23 Alza Corporation Neutral-cationic lipid for nucleic acid and drug delivery
FR2802422B1 (fr) 1999-12-21 2002-08-09 Capsulis Structures mixtes resultant de l'incorporation d'une macromolecule biologique, en particulier d'adn, dans une phase structuree d'amphiphiles et vesicules obtenues a partir de ces structures
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
CA2421087C (en) 2000-09-14 2012-03-27 Martin Gleave Antisense insulin-like growth factor binding protein (igfbp)-2 oligodeoxynucleotides for prostate and other endocrine tumor therapy
US20040043950A1 (en) * 2002-01-03 2004-03-04 Board Of Regents, The University Of Texas System WT1 antisense oligos for the inhibition of breast cancer
AU2003237616B2 (en) * 2002-01-17 2007-07-05 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
DK1530636T3 (da) 2002-08-21 2010-11-29 Univ British Columbia Behandling af melanomer ved reduktion af clusterinniveauet
EP2216029A3 (de) 2002-10-02 2010-12-22 The University Of British Columbia Oligonukleotide zur Behandlung von Prostatakrebs und anderen Krebserkrankungen
CA2520864A1 (en) 2003-03-31 2004-10-21 Alza Corporation Lipid particles having asymmetric lipid coating and method of preparing same
EP1684661A1 (de) 2003-08-14 2006-08-02 Boston Scientific Limited Medizinische schlingen
EP1667731B1 (de) * 2003-10-01 2013-05-22 The University Of British Columbia Bispezifisches oligonucleotid zur behandlung von malignen zns-erkrankungen
CA2542886A1 (en) 2003-11-05 2005-05-19 Neelima M. Bhat Enhanced b cell cytotoxicity of cdim binding antibody
KR20060130057A (ko) 2003-11-21 2006-12-18 알자 코포레이션 절단가능한 ｐｅｇ 표면 변형을 갖는 리포좀-ｄｎａ복합체에 의해 매개되는 유전자 송달
WO2005094899A1 (en) 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
EP3087949B1 (de) 2004-06-14 2018-07-25 Boston Scientific Limited System im zusammenhang mit implantierbaren stützschlingen
EP1814913B1 (de) 2004-11-05 2015-08-19 IGM Biosciences, Inc. Antikörperinduzierte zellmembranverletzung
JP4980919B2 (ja) * 2004-11-23 2012-07-18 ザ ユニバーシティー オブ ブリティッシュ コロンビア ユニバーシティー−インダストリー リエゾン オフィス Ｅｆｇシグナル伝達経路を混乱させる薬剤とクラステリンレベルを減少させるオリゴヌクレオチドとの併用による癌の治療
AU2006236453B2 (en) 2005-01-25 2012-02-23 Board Of Regents, The University Of Texas System Delivery of siRNA by neutral lipid compositions
JP5058969B2 (ja) * 2005-04-06 2012-10-24 ボストン サイエンティフィック リミテッド 尿道下の支持のためのシステム、装置および方法
WO2007008209A1 (en) 2005-07-13 2007-01-18 Boston Scientific Scimed Inc. Snap fit sling anchor system and related methods
WO2007014241A1 (en) 2005-07-25 2007-02-01 Boston Scientific Scimed, Inc. Pelvic floor repair system
US7981023B2 (en) * 2005-07-25 2011-07-19 Boston Scientific Scimed, Inc. Elastic sling system and related methods
US8273429B2 (en) * 2006-01-19 2012-09-25 Federal-Mogul World Wide, Inc. Fabric for end fray resistance and protective sleeves formed therewith and methods of construction
FR2900576B1 (fr) * 2006-05-03 2008-09-19 Centre Nat Rech Scient Procede de concentration extemporanee et reversible de liposomes.
WO2008106781A1 (en) * 2007-03-05 2008-09-12 The University Of British Columbia Treatment of squamous cell carcinoma with hsp27 antisense oligonucleotides and radiotherapy
US8900627B2 (en) * 2008-06-06 2014-12-02 Mirna Therapeutics, Inc. Compositions for the in vivo delivery of RNAi agents
ES2710109T3 (es) 2010-12-17 2019-04-23 Inst Nat Sante Rech Med Acidos nucleicos que se dirigen a TCTP para su uso en el tratamiento de cánceres quimiorresistentes u hormonorresistentes
US20120244209A1 (en) 2011-03-02 2012-09-27 Roth Jack A Tusc2 therapies
US9636201B2 (en) 2011-05-12 2017-05-02 Boston Scientific Scimed, Inc. Delivery members for delivering an implant into a body of a patient
US9113991B2 (en) 2011-05-12 2015-08-25 Boston Scientific Scimed, Inc. Anchors for bodily implants and methods for anchoring bodily implants into a patient's body
CN104254544B (zh) 2012-02-08 2017-04-26 Igm生物科学有限公司 Cdim结合蛋白及其用途
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
WO2014195754A1 (en) 2013-06-05 2014-12-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hydrophobically modified antisense oligonucleotides comprising a triple alkyl chain
WO2014195755A1 (en) 2013-06-05 2014-12-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hydrophobically modified antisense oligonucleotides comprising a ketal group
BR112018007611A2 (pt) * 2015-10-14 2018-10-23 Bio Path Holding Inc ácidos nucleicos p-etóxi para formulação lipossômica
CN108601765A (zh) 2015-12-18 2018-09-28 德克萨斯州大学系统董事会 用于早产管理的治疗剂
US20190216735A1 (en) * 2016-09-14 2019-07-18 Nanyang Technological University Liposomal formulations
BR112019005166A2 (pt) 2016-09-16 2019-07-02 Bio Path Holding Inc terapia de combinação com oligonucleotídeos antisense lipossômicos
US11278592B2 (en) 2016-10-12 2022-03-22 Board Of Regents, The University Of Texas System Methods and compositions for TUSC2 immunotherapy
JP7237009B2 (ja) * 2017-04-19 2023-03-10 バイオ－パス ホールディングス， インコーポレイテッド Ｓｔａｔ３阻害のためのｐ－エトキシ核酸
WO2018195250A1 (en) * 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for igf-1r inhibition
EP3628003A4 (de) * 2017-04-19 2021-01-20 Bio-Path Holdings, Inc. P-ethoxy-nukleinsäuren zur igf-1r-hemmung
IL297450A (en) 2020-04-20 2022-12-01 Univ Texas Compositions of biologically active dry powder, methods for production and use
US20230302154A1 (en) 2020-08-19 2023-09-28 The Board Of Regents Of The University Of Texas System Nanodrugs for targeted drug delivery and use thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (de) * 1977-08-05 1981-02-13 Battelle Memorial Institute
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4480041A (en) * 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
FR2540122B1 (fr) * 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US4721612A (en) * 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5094785A (en) * 1986-12-10 1992-03-10 Ciba Corning Diagnostics Corp. Process for stabilizing liposomes
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5030442A (en) * 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4950432A (en) * 1987-10-16 1990-08-21 Board Of Regents, The University Of Texas System Polyene microlide pre-liposomal powders
US5178875A (en) * 1991-01-14 1993-01-12 The Board Of Regents, The University Of Texas System Liposomal-polyene preliposomal powder and method for its preparation
US5188897A (en) * 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US4924624A (en) * 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
EP0397774A1 (de) * 1988-02-04 1990-11-22 Board Of Regents, The University Of Texas System Formulierung und anwendung von retinoiden für behandlung von krebs und anderen krankheiten
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5734033A (en) * 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5248671A (en) * 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
FR2644080A1 (fr) * 1989-03-13 1990-09-14 Trizac Jacques Dispositif de filtration et d'evacuation de petites particules, dechets et detritus, de natures diverses
ES2073574T3 (es) * 1989-04-18 1995-08-16 Vestar Inc Introduccion de liposomas en el tejido isquemico.
US5112962A (en) * 1989-04-19 1992-05-12 Northwestern University Labile anchors for solid phase polynucleotide synthesis
US5227170A (en) * 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
CA2033725C (en) * 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5665710A (en) * 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
HUT65614A (en) * 1990-04-30 1994-07-28 Isis Pharmaceuticals Inc Process for the oligonucleotide modulation of arachidonic acid metabolism
DE59108644D1 (de) * 1990-07-02 1997-05-07 Hoechst Ag Oligonucleotid-analoge mit terminalen 3'-3'-bzw. 5'-5'-Internucleotidverknüpfungen
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
JPH06501160A (ja) * 1990-09-17 1994-02-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞の増殖をコントロールするための方法及び組成物
US5271941A (en) * 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
DE4110085A1 (de) * 1991-03-27 1992-10-01 Boehringer Ingelheim Int 2'-o-alkyl-oligoribonukleotide, verfahren zu deren herstellung und deren verwendung als antisense-oligonukleotide
FR2677272B1 (fr) * 1991-06-05 1995-03-03 Biovecteurs As Vecteur particulaire a tropisme selectif, procede de preparation et composition pharmaceutique.
WO1992022303A1 (en) * 1991-06-18 1992-12-23 Temple University - Of The Commonwealth System Of Higher Education Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
US5525719A (en) * 1991-08-30 1996-06-11 Chemgenes Corporation N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
ATE239484T1 (de) * 1991-10-24 2003-05-15 Isis Pharmaceuticals Inc Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
CA2124673C (en) * 1991-12-04 2008-08-05 John Browse Fatty acid desaturase genes from plants
US5279957A (en) * 1992-04-30 1994-01-18 Washington University cDNA encoding human phospholipase A2 polypeptide
EP0646178A1 (de) * 1992-06-04 1995-04-05 The Regents Of The University Of California Expression kassette mit im säugetier wirt funktionnellen regulator sequenzen
US5320962A (en) * 1992-07-22 1994-06-14 Duke University DNA encoding the human A1 adenosine receptor
NL9201440A (nl) * 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
WO1994005259A1 (en) * 1992-09-02 1994-03-17 Georgetown University Method of encapsulating anthracycline glycosides in liposomes
US6001992A (en) 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
WO1994008625A1 (en) 1992-10-21 1994-04-28 Temple University - Of The Commonwealth System Of Higher Education Combination of antineoplastic agent and antisense oligonucleotides for treatment of cancer
US6015886A (en) * 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
US5417978A (en) * 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
FR2710074B1 (fr) * 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa Gène GRB3-3, ses variants et leurs utilisations.
CA2153251C (en) * 1993-11-05 1998-09-01 David Samuel Collins Liposome preparation and material encapsulation method
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5696248A (en) * 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US5908635A (en) * 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
IT1275862B1 (it) * 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
PT739898E (pt) * 1995-03-13 2002-03-28 Aventis Pharma Gmbh Mono-esteres de acidos fosfonucleicos processo para a sua preparacao e sua utilizacao
US6034235A (en) * 1995-06-01 2000-03-07 Tadamitsu Kishimoto Growth inhibitor for leukemia cell comprising antisense oligonucleotide derivative to wilms tumor gene (WT1)
US6326487B1 (en) * 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
JP4335310B2 (ja) * 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5756122A (en) * 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
NZ313264A (en) * 1995-08-01 1999-11-29 Novartis Ag Liposomal oligonucleotide compositions
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
DE19532553A1 (de) * 1995-09-04 1997-03-06 Hoechst Ag Verfahren zur Herstellung substituierter N-Ethyl-Glycinderivate
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US5874224A (en) * 1997-03-11 1999-02-23 Incyte Pharmaceuticals, Inc. Growth factor receptor binding protein
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
GB9711919D0 (en) * 1997-06-09 1997-08-06 Ciba Geigy Ag Oligonucleotide derivatives
CA2294579C (en) * 1997-06-23 2007-10-09 Sequus Pharmaceuticals, Inc. Liposome-entrapped polynucleotide composition and method
WO1999001139A1 (en) * 1997-07-03 1999-01-14 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
US7285288B1 (en) * 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6136965A (en) * 1998-07-02 2000-10-24 The Regents Of The University Of California Deoxynucleic alkyl and alkoxy thiourea compounds
US6211349B1 (en) * 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
US6211162B1 (en) * 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Also Published As

Publication number Publication date
EP0847272A2 (de) 1998-06-17
US20070202157A1 (en) 2007-08-30
PT847272E (pt) 2004-04-30
CA2228944C (en) 2011-10-18
WO1997007784A2 (en) 1997-03-06
ATE253897T1 (de) 2003-11-15
ES2210385T3 (es) 2004-07-01
AU6912996A (en) 1997-03-19
US20040005353A1 (en) 2004-01-08
US7754872B2 (en) 2010-07-13
WO1997007784A3 (en) 1997-04-24
DE69630691T2 (de) 2004-11-25
US5855911A (en) 1999-01-05
JP4291412B2 (ja) 2009-07-08
US6042846A (en) 2000-03-28
CA2228944A1 (en) 1997-03-06
US7176302B2 (en) 2007-02-13
EP0847272B1 (de) 2003-11-12
JPH11512099A (ja) 1999-10-19
DK0847272T3 (da) 2004-03-22

Similar Documents

Publication Publication Date Title
DE69630691D1 (de) LIPOSOMEN MIT p-ETHOXYOLIGONUKLEOTIDEN
ZA9811948B (en) Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom.
IL118419A0 (en) Delivery vehicles comprising stable lipid/nucleic acid complexes
GB9510718D0 (en) Antisense oligonucleotides
AU2946295A (en) Targeted gene delivery system
AU3222795A (en) Antitumor antisense oligonucleotides
CA2265917A1 (en) Method for using oligonucleotides having modified cpg dinucleosides
FR2739954B1 (fr) Machine de jeux, et notamment machine a sous
AU6617898A (en) An antisense oligonucleotide preparation method
AU8280798A (en) An improved method for design and selection of efficacious antisense oligonucleotides
WO1998019709A3 (en) Cationic reagents for transfection
EP0948513A4 (de) Verabreichungskonstrukt für gegenstrang-nukleinsäuren und methoden zu seiner anwendung
AU8938098A (en) Liposomes containing oligonucleotides
AU6535096A (en) Methods and means for targeted gene delivery
AU6355398A (en) Gaming machine with bonus mode
ZA985939B (en) Slot machine game and system with improved jackpot feature.
WO1997038010A3 (en) Fusogenic liposomes
AU6185096A (en) Bingo game management method
AU9663398A (en) Prize redemption system for games
ZA965931B (en) Transcorneal drug delivery system.
DE69635936D1 (de) Riechstofffreisetzungssystem
GB9620749D0 (en) Identifying antisense oligonucleotides
WO2001039744A3 (en) Radiation sensitive liposomes
EP1087753A4 (de) Zielgerichtetes liposomales arzneistoffverabreichungssystem
GB9505438D0 (en) Antisense oligonucleotides

Legal Events

Date Code Title Description
8364 No opposition during term of opposition